{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T06:32:57Z","timestamp":1787639577206,"version":"build-2736575974"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018628","name":"Scientific Research Foundation of Education Department of Anhui Province of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018628","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.bioorg.2025.108156","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T17:41:31Z","timestamp":1736530891000},"page":"108156","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Synthesis and biological evaluation of 4-((3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)oxy)quinoline derivatives as novel potential transforming growth factor-\u03b2 type 1 receptor inhibitors for hepatocellular carcinoma"],"prefix":"10.1016","volume":"155","author":[{"given":"Siyuan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fusheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caifang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bioorg.2025.108156_b0005","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41392-020-00436-9","article-title":"Targeting TGF\u03b2 signal transduction for cancer therapy","volume":"6","author":"Liu","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"7","key":"10.1016\/j.bioorg.2025.108156_b0010","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41580-018-0007-0","article-title":"Contextual determinants of TGF\u03b2 action in development, immunity and cancer","volume":"19","author":"David","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"10","key":"10.1016\/j.bioorg.2025.108156_b0015","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nrm3434","article-title":"TGF\u03b2 signalling in context","volume":"13","author":"Massagu\u00e9","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108156_b0020","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.cell.2011.08.050","article-title":"Master transcription factors determine cell-type-specific responses to TGF-\u03b2 signaling","volume":"147","author":"Mullen","year":"2011","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bioorg.2025.108156_b0025","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41568-021-00413-6","article-title":"Overcoming TGF\u03b2-mediated immune evasion in cancer","volume":"22","author":"Tauriello","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.bioorg.2025.108156_b0030","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41571-020-0403-1","article-title":"TGF\u03b2 biology in cancer progression and immunotherapy","volume":"18","author":"Derynck","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108156_b0035","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12943-022-01569-x","article-title":"Targeting TGF-\u03b2 signal transduction for fibrosis and cancer therapy","volume":"21","author":"Peng","year":"2022","journal-title":"Mol. Cancer"},{"issue":"11","key":"10.1016\/j.bioorg.2025.108156_b0040","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1002\/1878-0261.13146","article-title":"Dual inhibition of TGF-\u03b2 and PD-L1: a novel approach to cancer treatment","volume":"16","author":"Gulley","year":"2022","journal-title":"Mol. Oncol."},{"issue":"7693","key":"10.1016\/j.bioorg.2025.108156_b0045","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.bioorg.2025.108156_b0050","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1038\/s41416-024-02677-9","article-title":"Blockade of TGF-\u03b2 and PD-L1 by bintrafusp alfa promotes survival in preclinical ovarian cancer models by promoting T effector and NK cell responses","volume":"130","author":"Kment","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2025.108156_b0055","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.semcdb.2019.12.010","article-title":"TGF-\u03b21 \u2013 A truly transforming growth factor in fibrosis and immunity","volume":"101","author":"Lodyga","year":"2020","journal-title":"Semin. Cell Dev. Biol."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108156_b0060","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1124\/mol.65.3.744","article-title":"SB-505124 Is a Selective Inhibitor of Transforming Growth Factor-\u03b2 Type I Receptors ALK4, ALK5, and ALK7","volume":"65","author":"Stacey DaCosta","year":"2004","journal-title":"Mol. Pharmacol."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108156_b0065","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/sj.bjp.0706172","article-title":"Inhibition of TGF-\u03b2 signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis","volume":"145","author":"de Gouville","year":"2005","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.108156_b0070","doi-asserted-by":"crossref","unstructured":"Uhl M, Aulwurm S, Wischhusen Jr, Weiler M, Ma JY, Almirez R, Mangadu R, Liu Y-W, Platten M, Herrlinger U, Murphy A, Wong DH, Wick W, Higgins LS, Weller M. SD-208, a Novel Transforming Growth Factor \u03b2 Receptor I Kinase Inhibitor, Inhibits Growth and Invasiveness and Enhances Immunogenicity of Murine and Human Glioma Cells In vitro and In vivo. Cancer Res 2004, 64(21):7954-7961.","DOI":"10.1158\/0008-5472.CAN-04-1013"},{"issue":"2","key":"10.1016\/j.bioorg.2025.108156_b0075","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1124\/mol.118.112946","article-title":"Preclinical Evaluation of AZ12601011 and AZ12799734, Inhibitors of Transforming Growth Factor \u03b2 Superfamily Type 1 Receptors","volume":"95","author":"Spender","year":"2019","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108156_b0080","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejca.2007.10.008","article-title":"Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-\u03b2 kinase antagonist, in mice","volume":"44","author":"Bueno","year":"2008","journal-title":"Eur. J. Cancer"},{"issue":"10","key":"10.1016\/j.bioorg.2025.108156_b0085","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1021\/jm500115w","volume":"57","author":"Jin","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108156_b0090","unstructured":"W.T. Mcmillen, S. Joseph, S. Parthasarathy, H. Pei, J.S. Sawyer, D.W. Beight, G. Zhao, D.A. Coates, C.D. Wolfangel, Preparation of aminopyridyloxypyrazole compounds as TGFbR1 inhibitors, Eli Lilly and Company, USA, 2016. Application: US20160096823A1."},{"issue":"9","key":"10.1016\/j.bioorg.2025.108156_b0095","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S1470-2045(22)00446-6","article-title":"Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial","volume":"23","author":"Yamazaki","year":"2022","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108156_b0100","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1186\/s12885-023-11153-1","article-title":"A phase Ib\/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer","volume":"23","author":"Nadal","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bioorg.2025.108156_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112354","article-title":"Synthesis and biological evaluation of 4-(pyridin-4-oxy)-3-(3,3-difluorocyclobutyl)-pyrazole derivatives as novel potent transforming growth factor-\u03b2 type 1 receptor inhibitors","volume":"198","author":"Xu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"16","key":"10.1016\/j.bioorg.2025.108156_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127339","article-title":"Design, synthesis and biological activity evaluation of novel 4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl) oxy) pyridine-2-yl) amino derivatives as potent transforming growth factor-\u03b2 (TGF-\u03b2) type I receptor inhibitors","volume":"30","author":"Tan","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108156_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128552","article-title":"Synthesis and biological evaluation of 4-(pyridine-4-oxy)-3-(tetrahydro-2H-pyran-4-yl)-pyrazole derivatives as novel, potent of ALK5 receptor inhibitors","volume":"61","author":"Wang","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108156_b0120","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3389\/fcell.2020.00605","article-title":"On-Target Anti-TGF-\u03b2 Therapies Are Not Succeeding in Clinical Cancer Treatments: What Are Remaining Challenges?","volume":"8","author":"Teixeira","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bioorg.2025.108156_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107332","article-title":"Advances in the discovery of activin receptor-like kinase 5 (ALK5) inhibitors","volume":"147","author":"Mansour","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108156_b0130","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/13543776.2024.2346325","article-title":"Targeting the TGF-\u03b2 signaling pathway: an updated patent review (2021\u2013present)","volume":"34","author":"Guo","year":"2024","journal-title":"Expert Opin. Ther. Pat."},{"issue":"9","key":"10.1016\/j.bioorg.2025.108156_b0135","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/ardp.201400116","article-title":"Targeting the TGF-\u03b2 Receptor with Kinase Inhibitors for Scleroderma Therapy","volume":"347","author":"Cong","year":"2014","journal-title":"Arch Pharm (weinheim)"},{"issue":"7","key":"10.1016\/j.bioorg.2025.108156_b0140","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1021\/jm701199p","article-title":"Optimization of a Dihydropyrrolopyrazole Series of Transforming Growth Factor-\u03b2 Type I Receptor Kinase Domain Inhibitors. Discovery of an Orally Bioavailable Transforming Growth Factor-\u03b2 Receptor Type I Inhibitor as Antitumor Agent","volume":"51","author":"Li","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108156_b0145","doi-asserted-by":"crossref","unstructured":"E. Ling L, Lee W-C. TGF-Beta Type I Receptor (Alk5) Kinase Inhibitors in Oncology. Curr Pharm Biotechnol 2011, 12(12):2190-2202.","DOI":"10.2174\/138920111798808257"},{"issue":"23","key":"10.1016\/j.bioorg.2025.108156_b0150","doi-asserted-by":"crossref","first-page":"7901","DOI":"10.1021\/jm900807w","article-title":"Rapid Generation of a High Quality Lead for Transforming Growth Factor-\u03b2 (TGF-\u03b2) Type I Receptor (ALK5)","volume":"52","author":"Goldberg","year":"2009","journal-title":"J. Med. Chem."},{"issue":"25","key":"10.1016\/j.bioorg.2025.108156_b0155","doi-asserted-by":"crossref","first-page":"21614","DOI":"10.18632\/oncotarget.4308","article-title":"Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients","volume":"6","author":"Serova","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2025.108156_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113660","article-title":"Li H-y. Discovery and biological evaluation of phthalazines as novel non-kinase TGF\u03b2 pathway inhibitors","volume":"223","author":"Kharbanda","year":"2021","journal-title":"Eur. J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825000367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825000367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T02:44:39Z","timestamp":1740365079000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825000367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":32,"alternative-id":["S0045206825000367"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108156","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and biological evaluation of 4-((3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)oxy)quinoline derivatives as novel potential transforming growth factor-\u03b2 type 1 receptor inhibitors for hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108156","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108156"}}